Background/Aims We investigated the incidences of overall and site-specific malignancies and chemopreventive effects of statin, metformin, and aspirin in patients with ulcerative colitis.
Methods We collected data using the Health Insurance Review and Assessment claims database from January 2007 to April 2020.
Results The overall malignancy risk among the 35,189 ulcerative colitis patients was similar to that of the general population (standardized incidence ratio, 0.94; 95% confidence interval, 0.88–1.00). In male patients, standardized incidence ratios were high for thyroid cancer and low for stomach cancer, colorectal cancer, liver cancer, and lung cancer. Concurrently, standard incidence ratios were high for liver cancer and central nervous system cancer in female patients. While 122 cases of colorectal cancer occurred in the study patients, the standardized incidence ratio was 0.83 (95% confidence interval, 0.69–0.99). Treatment for ulcerative colitis was not associated with an increased adjusted hazard ratio, while comorbidities increased it for all malignancies. Treatment for ulcerative colitis was associated with an increased adjusted hazard ratio, while comorbidities did not increase it for colorectal cancer. After adjusting for age, sex, comorbidities, and ulcerative colitis treatment, statins showed a dose-dependent chemopreventive effect for all malignancies (P=0.002), while metformin and aspirin did not show any.
Conclusions In ulcerative colitis patients, standardized incidence ratios for all malignancies and colorectal cancer did not increase. Adjusted hazard ratios for all malignancies increased with comorbidities and those for colorectal cancer with ulcerative colitis treatment. Statins have a dose-dependent chemopreventive effect for all malignancies.
Citations
Citations to this article as recorded by
Thyroid disorders and inflammatory bowel disease: an association present in adults but also in children and adolescents Valeria Calcaterra, Francesca Penagini, Virginia Rossi, Luisa Abbattista, Alice Bianchi, Massimiliano Turzi, Lucia Cococcioni, Gianvincenzo Zuccotti Frontiers in Endocrinology.2025;[Epub] CrossRef
Does statin have a chemopreventive effect in patients with ulcerative colitis? Yoon Suk Jung Intestinal Research.2025; 23(2): 113. CrossRef
Soo-Kyung Park, Chang Hwan Choi, Jaeyoung Chun, Heeyoung Lee, Eun Sun Kim, Jae Jun Park, Chan Hyuk Park, Bo-In Lee, Yunho Jung, Dong-Il Park, Do Young Kim, Hana Park, Yoon Tae Jeen, IBD Research Group of the Korean Association for the Study of Intestinal Diseases
Intest Res 2020;18(1):18-33. Published online January 30, 2020
The treatment of inflammatory bowel disease (IBD) has been revolutionized for the last 10 years by the increasing use of immunomodulators and biologics. With immunosuppression of this kind, opportunistic infection is an important safety concern for patients with IBD. In particular, viral hepatitis is determined by the interaction between the virus and the host’s immunity, and the risk of reactivation increases if immunity is compromised by immunosuppression therapy. Parts of Asia, including Korea, still show intermediate endemicity for the hepatitis A virus and hepatitis B virus compared with the United States and Western Europe. Thus, members of IBD research group of the Korean Association for the Study of Intestinal Diseases have produced a guideline on the prevention and management of viral hepatitis in IBD.
Citations
Citations to this article as recorded by
Iranian Consensus Guideline for Pharmacotherapy with Biologics and Small Molecules Drugs in Adults with Inflammatory Bowel Diseases Niloofar Khoshnam-Rad, Homayoon Vahedi, Anahita Sadeghi, Mansoor Rastegarpanah, Soha Namazi, Amir Anushiravani, Ali Reza Sima, Shabnam Shahrokh, Sudabeh Alatab, Reza Malekzadeh Middle East Journal of Digestive Diseases.2023; 15(2): 83. CrossRef
Protective role of flavonoids quercetin and silymarin in the viral-associated inflammatory bowel disease: an updated review Elham Zarenezhad, Hussein T. Abdulabbas, Ahmed Shayaa Kareem, Seyed Amin Kouhpayeh, Silvia Barbaresi, Sohrab Najafipour, Abdulbaset Mazarzaei, Mitra Sotoudeh, Abdolmajid Ghasemian Archives of Microbiology.2023;[Epub] CrossRef
The impact of medication belief on adherence to infliximab in patients with Crohn’s disease Shuyan Li, Yan Ma, Hongling Sun, Zijun Ni, Shurong Hu, Yan Chen, Meijuan Lan Frontiers in Pharmacology.2023;[Epub] CrossRef
SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: expert consensus statement by KASID Yoo Jin Lee, Seong-Eun Kim, Yong Eun Park, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seung-Jae Myung Intestinal Research.2022; 20(2): 171. CrossRef
Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease Ji Min Lee, Shu-Chen Wei, Kang-Moon Lee, Byong Duk Ye, Ren Mao, Hyun-Soo Kim, Soo Jung Park, Sang Hyoung Park, Eun Hye Oh, Jong Pil Im, Byung Ik Jang, Dae Bum Kim, Ken Takeuchi Gut and Liver.2022; 16(3): 396. CrossRef
Antiviral Prophylaxis Against Hepatitis B Virus in Patients Treated with Anti-Tumor Necrosis Factor α Agents for Inflammatory Bowel Disease Eun Ae Kang, Jae Hee Cheon Gut and Liver.2022; 16(4): 501. CrossRef
Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment Soo Min Ahn, Jonggi Choi, Byong Duk Ye, Suk-Kyun Yang, Ji Seon Oh, Yong‑Gil Kim, Chang-Keun Lee, Bin Yoo, Sang Hyoung Park, Seokchan Hong Gut and Liver.2022; 16(4): 567. CrossRef
Inflammatory bowel disease in Korea: epidemiology and pathophysiology Jung Won Lee, Chang Soo Eun The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef
Viral Hepatitis in Patients with Inflammatory Bowel Disease Seung Hwan Shin, Sang Hyoung Park The Korean Journal of Gastroenterology.2022; 80(2): 51. CrossRef
Vaccination strategies for Korean patients with inflammatory bowel disease Yoo Jin Lee, Eun Soo Kim The Korean Journal of Internal Medicine.2022; 37(5): 920. CrossRef
Current Status of Opportunistic Infection in Inflammatory Bowel Disease Patients in Asia: A Questionnaire-Based Multicenter Study Hong Yang, Zhihua Ran, Meng Jin, Jia-Ming Qian Gut and Liver.2022; 16(5): 726. CrossRef
Do We Have an Opportunity to Avoid Opportunistic Infections in Asian Patients with Inflammatory Bowel Disease? Suhyun Park, Sang Hyoung Park Gut and Liver.2022; 16(5): 663. CrossRef
Natural history of inflammatory bowel disease: a comparison between the East and the West Eun Mi Song, Suk-Kyun Yang Intestinal Research.2022; 20(4): 418. CrossRef
Hepatobiliary Impairments in Patients with Inflammatory Bowel Diseases: The Current Approach Vlad Alexandru Ionescu, Gina Gheorghe, Valentin Nicolae Varlas, Ana Maria Alexandra Stanescu, Camelia Cristina Diaconu Gastroenterology Insights.2022; 14(1): 13. CrossRef
Viral infections in inflammatory bowel disease: Tips and tricks for correct management Vincenzo Craviotto, Federica Furfaro, Laura Loy, Alessandra Zilli, Laurent Peyrin-Biroulet, Gionata Fiorino, Silvio Danese, Mariangela Allocca World Journal of Gastroenterology.2021; 27(27): 4276. CrossRef
SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID Yoo Jin Lee, Seong-Eun Kim, Yong Eun Park, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seung-Jae Myung The Korean Journal of Gastroenterology.2021; 78(2): 117. CrossRef
Current status of inflammatory bowel diseases in Korea Suk-Kyun Yang Journal of the Korean Medical Association.2021; 64(9): 572. CrossRef
A clinical case of ulcerative colitis in a patient with viral hepatitis E. D. Kosmachova, M. S. Iakovenko, K. A. Yumukian South Russian Journal of Therapeutic Practice.2020; 1(3): 95. CrossRef